Often diagnosed in childhood or adolescence, retinitis pigmentosa (RP) is an inherited retinal disease causing progressive loss of night and peripheral vision. The condition often leads to legal and sometimes complete blindness.
What is Retinitis Pigmentosa?
Retinitis pigmentosa, also known as RP, refers to a group of inherited diseases causing retinal degeneration and a decline in vision. The retina is a thin piece of tissue lining the back of the eye. Rod and cone photoreceptors in the retina convert light into electrical signals that the brain interprets as vision. People with RP experience a gradual decline in their vision, because photoreceptors degenerate.
Forms of RP and related diseases include Usher syndrome, Leber congenital amaurosis, and Bardet-Biedl syndrome, among others.
Symptoms
Symptoms depend on whether rods or cones are initially involved. In most forms of RP, rods are affected first. Because rods are concentrated in the outer portions of the retina and are activated by dim light, their degeneration affects peripheral and night vision. Vision becomes more constricted over time. If and when the disease progresses and cones become affected, visual acuity, color perception, and central vision are diminished.
Night blindness is one of the earliest and most frequent symptoms of RP. People with mainly cone degeneration, however, first experience decreased central vision and reduced ability to discriminate colors and perceive details.
RP is typically diagnosed in children, adolescents and young adults. It is a progressive disorder. The rate of progression and degree of visual loss varies from person to person. Many people with RP are legally blind by age 40, with a central visual field of less than 20 degrees in diameter.
Inheritance
An estimated 100,000 people in the U.S. have RP, mainly caused by mutations (variations) in a single gene inherited from one or both parents. The mutated gene gives the wrong instructions to photoreceptor cells, telling them to make an incorrect protein or too little or too much protein. (Cells need the proper amount of particular proteins in order to function properly.) Mutations in dozens of genes have been linked to RP.
Genetic mutations can be passed from parent to offspring through one of three genetic inheritance patterns — autosomal recessive, autosomal dominant, or X-linked.
In autosomal recessive RP, both parents carry one copy of the mutated gene and one normal copy, but have no symptoms themselves. They are therefore referred to as unaffected carriers. Each of their children has a 25 percent chance of being affected by inheriting a mutated copy from each parent. If the child inherits one mutated copy from one parent, they will be an unaffected carrier.
In autosomal dominant RP, usually one parent is affected and is the only parent with a mutated copy of the gene. A child has a 50 percent chance of being affected through the inheritance of the mutated copy from. The unaffected parent genetics doesn’t play a known role in the inheritance of the disease.
In X-linked RP, the mutated gene for the disease is located on the X chromosome. Females have two X chromosomes and can carry the disease gene on one of their X chromosomes. Because they have a healthy version of the gene on their other X chromosome, carrier females are less frequently affected by X-linked diseases. Males have only one X chromosome (paired with one Y chromosome) and are therefore genetically susceptible to X-linked diseases. Males with X-linked diseases pass their Y chromosome to their sons, and therefore will never pass an X-linked disease to their sons. Female carriers have a 50 percent chance (or 1 chance in 2) of passing the X-linked disease gene to their daughters, who become carriers, and a 50 percent chance of passing the gene to their sons, who are then affected by the disease.
If a family member is diagnosed with RP, it is often advised that other members of the family also have an eye exam by a physician who is specially trained to detect and treat retinal degenerative disorders. Genetic counselors are excellent resources for discussing inheritability, family planning, genetic testing, and other related issues.
The most common genes associated with retinitis pigmentosa are PRPF31, PRPH2, RDH12, RHO, RPE65, ABCA4, MAK, MERTK, NR2E3, PDE6B, and RPGR.
Living with the Disease
There are many services and accommodative and assistive resources available to people and families with RP. Visit the Foundation’s Low Vision Resources page to learn about many of these resources. A low vision specialist can help recommend the resources that are right for you.
More information on managing RP is in the Newly Diagnosed section of this Web site.
Genetic Testing
Genetic testing is available for RP. It helps assess the risk of passing the disorder from parent to offspring. It also helps with attaining an accurate diagnosis. A patient with an accurate diagnosis is in a better position to understand which emerging treatment approaches and clinical trials are most appropriate for them.
Research and Clinical Trials
For the latest research advances for RP, refer to the Foundation publication Retinitis Pigmentosa: Research Advances.
View a list of current clinical trials, many made possible by Foundation support
RP page at www.ClinicalTrials.gov.
Join the fight and help us accelerate our mission
Next Section
Latest News
-
Oct 30, 2024
BlueRock’s Photoreceptor Cell Therapy to Move into Clinical Trial
The Foundation funded Dr. David Gamm for development of the induced pluripotent stem cell approach to be used in the trial.
-
Oct 29, 2024
Kiora Receives Authorization for Phase 2 Clinical Trial of its Photoswitch for Advanced RP
The 36-participant trial will take place at multiple sites in Australia.
-
Oct 23, 2024
Opus Genetics, Ocuphire Merger to Boost Advancement of Several IRD Gene Therapies
Merger will provide additional capital for gene therapy development.
-
Sep 26, 2024
Vision: A Memoir of Blindness and Justice — A New York Times Editor’s Pick
“Tatel’s humility and tenacity shine. The result is a stirring reflection on an extraordinary life,” Publishers Weekly
-
Jun 5, 2024
Antabuse Moves into Clinical Trial for People with RP
Researchers believe the FDA-approved drug can reduce the hyperactivity of ganglion cells to improve vision.
-
May 22, 2024
Foundation Fighting Blindness Awards Inaugural Grants in PRPH2 and Associated Retinal Diseases Program
Advancing Research Solutions for PRPH2-Associated Retinal Diseases.
-
Mar 25, 2024
BlueRock Therapeutics and Foundation Fighting Blindness announce collaboration to expand the Uni-Rare natural history study of patients living with inherited retinal diseases
Collaboration will add a new multi-gene cohort of patients living with inherited retinal diseases. Data insights from the new study cohort will inform the future clinical trial design for BlueRock’s pipeline of cell therapies for treating blindness.
-
Sep 7, 2023
Foundation Funds 25 New Grants Totaling $15.1 Million in FY23
The global leader in retinal degenerative disease research supports a total of 93 research grants in its portfolio.
-
Nov 10, 2022
Foundation Launching its Largest Natural History Study to Date for 1,500 People with Inherited Retinal Diseases Caused by Rare Mutated Genes
Uni-Rare Study will improve clinical understanding of more IRDs and boost development of potential therapies.
-
Sep 15, 2022
RD Fund Participates in a €75 Million Series B for SparingVision
Proceeds to fund first, in-human trials of breakthrough gene-agnostic therapy products and advance CRISPR-based genome editing portfolio.
-
Jan 29, 2021
Renowned Pioneers in Ophthalmology Join SparingVision’s Scientific Advisory Board
Development of lead asset SPVN06 to further benefit from high-level Clinical Advisory Board
-
Sep 24, 2020
Foundation Fighting Blindness To Jointly Host Online Continuing Medical Education (CME, COPE) Webinar
The event will review best practices for care and management of patients with inherited retinal diseases such as retinitis pigmentosa, Usher syndrome, and Stargardt disease.
-
Aug 21, 2020
Foundation Fighting Blindness Commits $6.5 Million for New Retinal Disease Research Grants
New grants include development of CRISPR/Cas9 gene-editing treatments, new disease models, and a retinal regeneration therapy
-
Mar 31, 2020
COVID-19 Resources
The Foundation Fighting Blindness is closely monitoring the COVID-19 situation and its impact on the IRD community.
-
Feb 14, 2020
Unstoppable: With Her “Trusty Guide Shiloh” By Her Side, Janni Lehrer-Stein Travels the World and Advocates for Disability Rights
People with disabilities are no different from anyone else. We all have strengths and challenges, and we all seek to be fully engaged in society. Treating blind people differently, either as incapable of conducting everyday tasks in life, or conversely, acting as though our ability to conduct even the most mundane chore is remarkable can be discouraging.
-
Feb 6, 2020
ProQR Therapeutics Teams Up with the Foundation Fighting Blindness and Blueprint Genetics to Support the My Retina Tracker® Program for People Living with Inherited Retinal Diseases
My Retina Tracker Program is the highest volume IRD genetic testing program in the U.S.
-
Nov 27, 2019
Foundation Fighting Blindness Launches Natural History Study for People with RP Caused by EYS Gene Mutations
Known as Pro-EYS, the study will help researchers design clinical trials for potential therapies
-
Oct 2, 2019
Blueprint Genetics, InformedDNA and the Foundation Fighting Blindness launch an open access program for patients with inherited retinal disease in the United States
The program will offer patients with inherited retinal disease no-cost genetic testing and genetic counseling in the United States. Look for updated information on how to participate to be posted in mid-October, with program registration starting shortly thereafter.
-
Jun 3, 2019
Tackling the Next Gene Therapy Challenge: Autosomal Dominant Diseases
A discussion of strategies concerning the development of autosomal dominant disease therapies at the Translational Research Acceleration Program (TRAP) in November 2013.
-
Jul 19, 2018
Foundation Fighting Blindness Urges Congress to Pass ‘Eye-Bonds’ Legislation
Bill Introduced in U.S. House Would Speed Up Cures for Blindness
-
Jun 8, 2018
Foundation Fighting Blindness and CheckedUp® Partner to Educate Retinal-Disease Patients About Research, Resources, and Emerging Therapies During Doctor Visits
The Foundation Fighting Blindness (the Foundation) and CheckedUp have formed a collaborative partnership to deliver patient-friendly diagnostic and disease-management information to people with retinal diseases such as age-related macular degeneration, retinitis pigmentosa, and Stargardt disease during their visits to eye doctors.
-
Jan 9, 2018
A Retinal Research Nonprofit Paves the Way for Commercializing Gene Therapies
AN EMERGING, vision-restoring gene therapy for a devastating retinal disease is poised for Food and Drug Administration (FDA) approval. If it gets the regulatory nod, it will be the first gene therapy to receive FDA approval for the eye or an inherited condition.
Related Resources
Sep 25, 2020
ProQR Announces Virtual Presentations at Scientific Conferences
ProQR Therapeutics N.V. (Nasdaq:PRQR), a company dedicated to changing lives through the creation of transformative RNA therapies for severe genetic rare diseases, today announced virtual presentations at the Ophthalmology Futures Retina Forum, European Society of Retina Specialists (Euretina) congress and the Annual Meeting of the American Academy of Optometry (AAOpt).